Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia: Protocol amendment allows for change in dose limiting toxicity (DLT) criteria for future enrolled subjects (PR Newswire, 2021)
Keywords: Brain cancer; Cardiotoxicity; Clinical trials; Drug dosages; FDA approval; Leukemia; Lungs; Metastasis; Pharmaceutical industry; Toxicity; Tumors; United States--US; HOUSTON